{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T02:44:53Z","timestamp":1773715493745,"version":"3.50.1"},"reference-count":43,"publisher":"Medwave Estudios Limitada","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medwave"],"DOI":"10.5867\/medwave.2018.03.7220","type":"journal-article","created":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T15:03:39Z","timestamp":1531494219000},"page":"e7220-e7220","source":"Crossref","is-referenced-by-count":7,"title":["Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile"],"prefix":"10.5867","volume":"18","author":[{"given":"Susana","family":"Aceituno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irmina","family":"Gozalbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilena","family":"Appierto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Liz\u00e1n T","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3888","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009 Jan;23(1):3-9. | CrossRef | PubMed |","DOI":"10.1038\/leu.2008.291"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538-48. | CrossRef | PubMed |","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004 Oct 28;351(18):1860-73. | PubMed |","DOI":"10.1056\/NEJMra041875"},{"key":"ref3","unstructured":"GLOBOCAN 2012. Estimated cancer Incidence, Mortality, Prevalence and Disability-adjusted life years (DALYs) Worldwide in 2012. [on line] | Link |"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Sonneveld P, De Wit E, Moreau P. How have evolutions in strategies for the treatment of relapsed\/refractory multiple myeloma translated into improved outcomes for patients? Crit Rev Oncol Hematol. 2017 Apr;112:153-170. | CrossRef | PubMed |","DOI":"10.1016\/j.critrevonc.2017.02.007"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv52-iv61. | CrossRef | PubMed |","DOI":"10.1093\/annonc\/mdx096"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, et al. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. J Natl Compr Canc Netw. 2016 Apr;14(4):389-400. | PubMed |","DOI":"10.6004\/jnccn.2016.0046"},{"key":"ref7","unstructured":"Sociedad Chilena de Hematolog\u00eda SOCHIHEM 2014. Gu\u00edas pr\u00e1cticas cl\u00ednicas para diagn\u00f3stico y tratamiento de mieloma m\u00faltiple. 2014. hematologia.org [On line] | Link |"},{"key":"ref8","unstructured":"National Institute for Health and Care Excellence (NICE). Lenalidomide for treating multiple myeloma after 1 prior treatment with bortezomib (part-review of TA171): appraisal consultation document. nice.org.uk [on line]. | Link |"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Eur J Health Econ. 2013 Jun;14(3):367-72. | CrossRef | PubMed |","DOI":"10.1007\/s10198-013-0471-6"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M; ISPOR-SMDM Modeling Good Research Practices Task Force. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. Med Decis Making. 2012 Sep-Oct;32(5):678-89. | PubMed |","DOI":"10.1177\/0272989X12454941"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Minacori R, Bonastre J, Lueza B, Marguet S, Levy P. How to Model Survival In Cost-Effectiveness Analysis? Differences Between Markov and Partitioned Survival Analysis Models. Value Health. 2015 Nov;18(7):A704. | CrossRef | PubMed |","DOI":"10.1016\/j.jval.2015.09.2639"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22;357(21):2133-42. | PubMed |","DOI":"10.1056\/NEJMoa070596"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007 Nov 22;357(21):2123-32. | PubMed |","DOI":"10.1056\/NEJMoa070594"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Taverna C, Voegeli J, Trojan A, Olie RA, von Rohr A. Effective response with bortezomib retreatment in relapsed multiple myeloma--a multicentre retrospective survey in Switzerland. Swiss Med Wkly. 2012 Apr 27;142:w13562. | CrossRef | PubMed |","DOI":"10.4414\/smw.2012.13562"},{"key":"ref15","unstructured":"FDA. Velcade [Bortezomib] for injection. [on line] | Link |"},{"key":"ref16","unstructured":"Myeloma Pathways 2007-9 data. Haematological Malignancy Research Network, York UK."},{"key":"ref17","unstructured":"FDA. REVLIMID [lenalidomide] capsules, for oral use. [on line]. | Link |"},{"key":"ref18","unstructured":"Ministerio de Salud (MINSAL) Gobierno de Chile. Encuesta Nacional de Salud ENS Chile 2009-2010. [on line] | Link |"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Cont\u00e9 LG, Figueroa MG, Lois VV, Cabrera C ME, Le\u00f3n RA, Garc\u00eda LH, Rojas R H. [Clinical features and survival of Chilean patients with multiple myeloma]. Rev Med Chil. 2007 Sep;135(9):1111-7. | PubMed |","DOI":"10.4067\/S0034-98872007000900003"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"van Agthoven M, Segeren CM, Buijt I, Uyl-de Groot CA, van der Holt B, Lokhorst HM, et al. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II\/III multiple myeloma; a prospective randomised phase III study. Eur J Cancer. 2004 May;40(8):1159-69. | PubMed |","DOI":"10.1016\/j.ejca.2004.01.019"},{"key":"ref21","unstructured":"Ministerio de Salud, Gobierno de Chile. Gu\u00eda Metodol\u00f3gica para la Evaluaci\u00f3n Econ\u00f3mica de intervenciones en Salud en Chile. Santiago, Chile: Minsal;2013:16-36. | Link |"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Roberts M1, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2. Value Health. 2012 Sep-Oct;15(6):804-11. | CrossRef | PubMed |","DOI":"10.1016\/j.jval.2012.06.016"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Becerril-Montekio V, de Dios Reyes J, Manuel A. Sistema de salud de Chile. Salud Publica Mex. 2011;53(SUPPL.2):s132-42. | Link |","DOI":"10.1590\/S0036-36342011000500003"},{"key":"ref24","unstructured":"National Institute for health and Care Excellence (NICE). Single Technology Appraisal (STA) of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171). Celgene submission of evidence. nice.org.uk [on line]. | Link |"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Coffey JT, Brandle M, Zhou H, Marriott D, Burke R, Tabaei BP, et al. Valuing health-related quality of life in diabetes. Diabetes Care. 2002 Dec;25(12):2238-43. | PubMed |","DOI":"10.2337\/diacare.25.12.2238"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Ossa DF, Briggs A, McIntosh E, Cowell W, Littlewood T, Sculpher M. Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods. Pharmacoeconomics. 2007;25(3):223-37. | PubMed |","DOI":"10.2165\/00019053-200725030-00005"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. Br J Cancer. 2006 Sep 18;95(6):683-90. | PubMed |","DOI":"10.1038\/sj.bjc.6603326"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Cykert S, Joines JD, Kissling G, Hansen CJ. Racial differences in patients' perceptions of debilitated health states. J Gen Intern Med. 1999 Apr;14(4):217-22. | PubMed |","DOI":"10.1046\/j.1525-1497.1999.00320.x"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Mathias SD, Prebil LA, Putterman CG, Chmiel JJ, Throm RC, Comerota AJ. A Health-Related Quality of Life Measure in Patients with Deep Vein Thrombosis: A Validation Study. Ther Innov Regul Sci 1999 Oct 1;33(4):1173\u201387. | CrossRef |","DOI":"10.1177\/009286159903300421"},{"key":"ref30","unstructured":"Chile Compra. Pagina Web. mercadopublico.cl [on line] | Link |"},{"key":"ref31","unstructured":"Aranceles FONASA. Modalidad de Libre Elecci\u00f3n. Planilla MLE 2018. [on line] | Link |"},{"key":"ref32","unstructured":"Aranceles FONASA. Modalidad de Atenci\u00f3n Institucional. MAI 2018. [on line]. | Link |"},{"key":"ref33","unstructured":"FONASA. Alivio del Dolor y Cuidados Paliativos por C\u00e1ncer Avanzado. Disponible en: Alivio del Dolor y Cuidados Paliativos por C\u00e1ncer Avanzado. [on line]"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Vargas CL, Espinoza MA, Giglio A, Soza A. Cost Effectiveness of Daclatasvir\/Asunaprevir Versus Peginterferon\/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Na\u00efve Patients in Chile. PLoS One. 2015 Nov 6;10(11):e0141660. | CrossRef | PubMed |","DOI":"10.1371\/journal.pone.0141660"},{"key":"ref35","unstructured":"Pamidronate Summary of Product Characteristics. [on line] | Link |"},{"key":"ref36","unstructured":"Banco Central de Chile. Base de datos estad\u00edsticos [on line]. | Link |"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015 Feb 1;93(2):118-24. | CrossRef | PubMed |","DOI":"10.2471\/BLT.14.138206"},{"key":"ref38","unstructured":"Banco central de Chile. Indicadores macroecon\u00f3micos. Cuarto trimestre del 2017 [on line]. | Link |"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"M\u00f6ller J, Nicklasson L, Murthy A. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib. J Med Econ. 2011;14(6):690-7. | CrossRef | PubMed |","DOI":"10.3111\/13696998.2011.611841"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Fragoulakis V, Kastritis E, Psaltopoulou T, Maniadakis N. Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece. Cancer Manag Res. 2013 Apr 10;5:37-48. | CrossRef | PubMed |","DOI":"10.2147\/CMAR.S43373"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005 Jun 16;352(24):2487-98. | PubMed |","DOI":"10.1056\/NEJMoa043445"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, L\u00f6thgren M. The cost-effectiveness of bortezomib in relapsed\/refractory multiple myeloma: Swedish perspective. Eur J Haematol. 2010 Dec;85(6):484-91. | CrossRef | PubMed |","DOI":"10.1111\/j.1600-0609.2010.01526.x"}],"container-title":["Medwave"],"original-title":[],"link":[{"URL":"https:\/\/www.medwave.cl\/link.cgi\/Medwave\/Estudios\/EvalEconom\/7220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T19:49:51Z","timestamp":1571600991000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.medwave.cl\/link.cgi\/English\/Original\/HealthEconom\/7222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":43,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2018,6,26]]}},"URL":"https:\/\/doi.org\/10.5867\/medwave.2018.03.7220","relation":{},"ISSN":["0717-6384"],"issn-type":[{"value":"0717-6384","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,26]]}}}